18854 Federal Register / Vol. 80, No. 67 / Wednesday, April 8, 2015 / Notices 

behavior after notification by the blood 

center. This will be accomplished using 

a new audio computer-assisted 

structured interview (ACASI) (See 

Attachment 1, Brazil HIV Follow up 

ACASI Survey). The third aim will 

consist of asking HIV-positive blood 

donors about ways to improve the 

disclosure of HIV risks during donor 

eligibility assessment to better 

understand the motivating factors that 

drive higher risk persons to donate 

blood. 

Because our study will build off the 

routine blood donor procedures in four 

large blood banks in Brazil, it may lead 

to more informed conversations around 

and possible changes in donor 

screening, notification and counseling 

policies in Latin America. Results of 

these three aims may also help to better 

integrate blood centers within the 

context of broader HIV testing, 

counseling and treatment sites in Brazil. 

Similarly, in the US little is known 

about donor behavior after notification 

of testing results by blood centers. The 

results from this study can be used to 

develop insights and hypotheses 

focused on developing improved 

strategies for notification and 

counseling of HIV-positive (or hepatitis 

C or B-positive) donors in the U.S. 

This proposed study’s findings will 

also yield insights into improved 

methods for donor self-selection and 

qualification post donation, which will 

serve to decrease the frequency of 

higher-risk persons acting as donors. 

Our findings on improved methods for 

Brazilian donor notification and linkage 

to health care services may also be 

applicable to developed countries, 

including the U.S. Results of the Brazil 

Notification Study will identify how to 

improve notification and counseling 

strategies that increase the number of 

HIV-positive donors seeking prompt 

medical care. This might ultimately 

boost strategies to prevent secondary 

HIV transmission and reduce the risk of 

transfusion-transmission. 

In addition to the traditional route of 

scientific dissemination through peer 

reviewed scientific publication, 

previous REDS and REDS–II study data 

were the subject of numerous requested 

presentations by Federal and nonFederal agencies, including the FDA 

Blood Products Advisory Committee, 

the HHS Advisory committee on Blood 

Safety and Availability, the AABB 

Transfusion-Transmitted Diseases 

Committee, and the Americas Blood 

Centers (ABC). We anticipate similar 

requests for results generated from this 

study. Data collected in this proposed 

HIV Notification study of donors will be 

of practical use to the blood banking 

and infectious disease communities in 

the U.S. and internationally. 

OMB approval is requested for 3 

years. There are no costs to respondents 

other than their time. The total 

estimated annualized burden hours are 

229. 

ESTIMATED ANNUALIZED BURDEN HOURS

Form name Type of 

respondent 

Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

Estimated 

total annual 

burden hours 

requested 

ACASI Questionnaire—Informed Consent .............. Adults ........................ 275 1 10/60 46 

ACASI Questionnaire ............................................... Adults ........................ 275 1 40/60 183 

Dated: April 2, 2015. 

Lynn Susulske, 

NHLBI Project Clearance Liaison, National 

Institutes of Health. 

[FR Doc. 2015–07980 Filed 4–7–15; 8:45 am] 

<FNP> 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of meetings of the National 

Diabetes and Digestive and Kidney 

Diseases Advisory Council. 

The meetings will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Diabetes and 

Digestive and Kidney Diseases Advisory 

Council. 

Date: May 13, 2015. 

Open: 8:30 a.m. to 12:00 p.m. 

Agenda: To present the Director’s Report 

and other scientific presentations. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Conference 

Room 10, Bethesda, MD 20892. 

Closed: 4:15 p.m. to 4:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Conference 

Room 10, Bethesda, MD 20892. 

Contact Person: Brent B. Stanfield, Ph.D., 

Director, Division of Extramural Activities, 

National Institutes of Diabetes and Digestive 

and Kidney Diseases, 6707 Democracy Blvd., 

Room 715, MSC 5452, Bethesda, MD 20892, 

(301) 594–8843, stanfibr@niddk.nih.gov. 

Name of Committee: National Diabetes and 

Digestive and Kidney Diseases Advisory 

Council; Kidney, Urologic and Hematologic 

Diseases Subcommittee. 

Date: May 13, 2015. 

Open: 1:00 p.m. to 2:00 p.m. 

Agenda: To review the Division’s scientific 

and planning activities. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Conference 

Room 7, Bethesda, MD 20892. 

Closed: 2:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Conference 

Room 7, Bethesda, MD 20892. 

Contact Person: Brent B. Stanfield, Ph.D., 

Director, Division of Extramural Activities, 

National Institutes of Diabetes and Digestive 

and Kidney Diseases, 6707 Democracy Blvd., 

Room 715, MSC 5452, Bethesda, MD 20892, 

(301) 594–8843, stanfibr@niddk.nih.gov. 

Name of Committee: National Diabetes and 

Digestive and Kidney Diseases Advisory 

Council; Digestive Diseases and Nutrition 

Subcommittee. 

Date: May 13, 2015 

Open: 1:00 p.m. to 2:30 p.m. 

Agenda: To review the Division’s scientific 

and planning activities. 


asabaliauskas on DSK5VPTVN1PROD with NOTICES
Federal Register / Vol. 80, No. 67 / Wednesday, April 8, 2015 / Notices 18855 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Conference 

Room 6, Bethesda, MD 20892. 

Closed: 2:30 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Conference 

Room 6, Bethesda, MD 20892. 

Contact Person: Brent B. Stanfield, Ph.D., 

Director, Division of Extramural Activities, 

National Institutes of Diabetes and Digestive 

and Kidney Diseases, 6707 Democracy Blvd., 

Room 715, MSC 5452, Bethesda, MD 20892, 

(301) 594–8843, stanfibr@niddk.nih.gov. 

Name of Committee: National Diabetes and 

Digestive and Kidney Diseases Advisory 

Council; Diabetes, Endocrinology and 

Metabolic Diseases Subcommittee. 

Date: May 13, 2015. 

Open: 2:00 p.m. to 4:00 p.m. 

Agenda: To review the Division’s scientific 

and planning activities. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Conference 

Room 10, Bethesda, MD 20892. 

Closed: 1:00 p.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Conference 

Room 10, Bethesda, MD 20892. 

Contact Person: Brent B. Stanfield, Ph.D., 

Director, Division of Extramural Activities, 

National Institutes of Diabetes and Digestive 

and Kidney Diseases, 6707 Democracy Blvd., 

Room 715, MSC 5452, Bethesda, MD 20892, 

(301) 594–8843, stanfibr@niddk.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport) and to state the purpose of their 

visit. 

Information is also available on the 

Institute’s/Center’s home page: 

www.niddk.nih.gov/fund/divisions/DEA/

Council/coundesc.htm, where an agenda and 

any additional information for the meeting 

will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: April 2, 2015. 

David Clary, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2015–07983 Filed 4–7–15; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases;. Notice 

of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; LRP Fiscal Year 

2015 Applications. 

Date: April 24, 2015. 

Time: 2:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: John F. Connaughton, 

Ph.D., Chief, Training and Mentored 

Research Section, REVIEW BRANCH, DEA, 

NIDDK, NATIONAL INSTITUTES OF 

HEALTH, ROOM 753, 6707 DEMOCRACY 

BOULEVARD, BETHESDA, MD 20892–5452, 

(301) 594–7797, 

connaughtonj@extra.niddk.nih.gov. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; PAR–14–301: 

NIDDK Central Repositories Non-Renewable 

Samples Access (X01). 

Date: May 26, 2015. 

Time: 2:00 p.m. to 4:00 p.m. 

AGENDA: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892, (Telephone 

Conference Call). 

Contact Person: NAJMA BEGUM, PH.D., 

SCIENTIFIC REVIEW OFFICER, REVIEW 

BRANCH, DEA, NIDDK, NATIONAL 

INSTITUTES OF HEALTH, ROOM 749, 6707 

DEMOCRACY BOULEVARD, BETHESDA, 

MD 20892–5452, (301) 594–8894, 

begumn@niddk.nih.gov. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; Biomarkers for 

Diabetes and Kidney Diseases using 

Biosamples from NIDDK Repository (R01– 

PAR–13–228). 

Date: May 28, 2015. 

Time: 2:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892, (Telephone 

Conference Call). 

Contact Person: NAJMA BEGUM, PH.D., 

SCIENTIFIC REVIEW OFFICER, REVIEW 

BRANCH, DEA, NIDDK, NATIONAL 

INSTITUTES OF HEALTH, ROOM 749, 6707 

DEMOCRACY BOULEVARD, BETHESDA, 

MD 20892–5452, (301) 594–8894, 

begumn@niddk.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: April 2, 2015. 

David Clary, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2015–08167 Filed 4–7–15; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Coast Guard 

[Docket No.—USCG–2015–0201] 

Chemical Transportation Advisory 

Committee; Vacancies 

AGENCY: Coast Guard, DHS 

ACTION: Request for applications. 

SUMMARY: The Coast Guard seeks 

applications for membership on the 

Chemical Transportation Advisory 

Committee. The Chemical 

Transportation Advisory Committee 

provides advice and makes 

recommendations on matters relating to 

the safe and secure marine 

transportation of hazardous materials 

activities insofar as they relate to 

matters within the United States Coast 

Guard’s jurisdiction. 

DATES: Completed applications should 

reach the Coast Guard on or before June 

8, 2015. 

ADDRESSES: Applicants should send a 

cover letter expressing interest in an 

appointment to the Chemical 

Transportation Advisory Committee that 

also identifies which membership 

category the applicant is applying 

under, along with a resume detailing the 

applicant’s experience via one of the 

following methods: 

• By Email: cristina.e.nelson@

uscg.mil. 

• By Fax: (202) 372–8380. 

• By Mail: Lieutenant Cristina 

Nelson, Alternate Designated Federal 


asabaliauskas on DSK5VPTVN1PROD with NOTICES